FSLCX
Price
$20.85
Change
+$0.08 (+0.39%)
Updated
Jul 31 closing price
Net Assets
1.34B
NAESX
Price
$141.37
Change
-$0.34 (-0.24%)
Updated
Jul 31 closing price
Net Assets
188.57B
Interact to see
Advertisement

FSLCX vs NAESX

FSLCX vs NAESX Comparison Chart in %
View a ticker or compare two or three
VS
FSLCX vs. NAESX commentary
Aug 03, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FSLCX is a Hold and NAESX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
NAESX has more cash in the bank: 189B vs. FSLCX (1.34B). NAESX pays higher dividends than FSLCX: NAESX (1.10) vs FSLCX (0.14). FSLCX was incepted earlier than NAESX: FSLCX (28 years) vs NAESX (66 years). FSLCX (0.86) is less costly to investors than NAESX (0.17). FSLCX is a more actively managed with annual turnover of: 159.00 vs. NAESX (17.00). FSLCX (0) and NAESX (0) have matching initial minimum investment requirements. NAESX annual gain was more profitable for investors over the last year : 22.56 vs. FSLCX (12.52). NAESX return over 5 years is better than : 34.95 vs. FSLCX (-4.91).
FSLCXNAESXFSLCX / NAESX
Total Expense Ratio0.860.17506%
Annual Report Gross Expense Ratio0.860.17506%
Fund Existence28 years66 years-
Gain YTD13.00814.56389%
Front LoadN/AN/A-
Min. Initial Investment00-
Min. Initial Investment IRAN/AN/A-
Net Assets1.34B189B1%
Annual Yield % from dividends0.141.1013%
Returns for 1 year12.5222.5656%
Returns for 3 years29.0043.3067%
Returns for 5 years-4.9134.95-14%
Returns for 10 years18.82155.2812%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VMMSX32.150.39
+1.23%
Vanguard Emerg Mkts Sel Stk Inv
VRGWX936.977.54
+0.81%
Vanguard Russell 1000 Growth Index I
GIDWX20.040.13
+0.65%
Goldman Sachs US Eq Div and Premium R6
CAVAX18.710.04
+0.21%
SEI Catholic Values Equity F (SCVT)
RYOIX86.56-2.00
-2.26%
Rydex Biotechnology Inv